Artelo Unvails New Data On ART26.12 Demonstrating Positive Effects In Multiple Models Of Neuropathic Pain
Portfolio Pulse from Vuk Zdinjak
Artelo Biosciences presented preclinical data on its FABP5 inhibitor, ART26.12, showing positive effects in multiple models of neuropathic pain. The company expects to receive pre-IND meeting minutes from the FDA during Q3 this year.
June 27, 2023 | 3:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Artelo Biosciences' ART26.12 shows positive effects in neuropathic pain models, with FDA pre-IND meeting minutes expected in Q3.
The positive preclinical data on ART26.12 indicates potential for the treatment of neuropathic pain, a market valued at $7.6 billion. The expected FDA pre-IND meeting minutes in Q3 will mark a significant milestone for the development of ART26.12, which could positively impact Artelo Biosciences' stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100